New Psilocybin-Like Drugs for Brain Receptor Diseases
This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases.
Original patent title: “Psilocybin analogs, salts, compositions, and methods of use”
This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases. Granted in 2026.
Coverage
What does this patent actually cover?
This patent focuses on creating new chemical compounds, referred to as "psilocin compounds" or "analogs," that are chemically similar to psilocin. These compounds are designed to act as "serotonin 5-HT2 receptor agonists," meaning they activate specific serotonin receptors in the brain. The goal is to use these new compounds in "pharmaceutical compositions" to treat medical conditions associated with these 5-HT2 receptors. For example, a new psilocin analog could be formulated into a pill to treat a mental health condition like depression, aiming to provide therapeutic benefits by modulating brain activity through these specific receptors. Due to the lack of available claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → text, specific claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → elements cannot be referenced.
The gap
What does this patent NOT cover?
- Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives.
- Does not cover compounds that do not primarily function as 'serotonin 5-HT2 receptor agonists'.
- Does not cover non-chemical or non-pharmaceutical treatments for diseases associated with 5-HT2 receptors.
- Does not cover methods of use that are not for the treatment of diseases.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in synthesizing new chemical structures, or 'analogs,' of psilocin. These analogs are engineered to interact with the brain's serotonin 5-HT2 receptors in specific ways, potentially offering advantages like improved stability, controlled duration of action, or reduced unwanted side effects compared to the natural compound.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Novel psychedelic-assisted therapies for major depressive disorder
Drug candidates for generalized anxiety disorder
Pharmaceutical formulations for post-traumatic stress disorder (PTSD) treatment
Compounds for cluster headache treatment
Why it matters
The bigger picture
Psilocybin and related compounds are being extensively researched for their potential to treat serious mental health conditions like depression, anxiety, and PTSD. This patent contributes to the development of novel drug candidates that could offer improved therapeutic profiles, such as better safety, efficacy, or duration of action, compared to naturally occurring psychedelics. It aims to expand the toolkit for addressing significant unmet medical needs in psychiatry and neurology.
Filed
March 17, 2022
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Many biotech and pharmaceutical companies are actively researching and developing psychedelic-inspired compounds for therapeutic use. Companies like Compass Pathways, MindMed, and Atai Life Sciences are prominent players in this space, focusing on creating new chemical entities and optimizing existing ones for mental health treatments. Academic institutions and smaller startups are also contributing to the discovery of novel compounds and their applications.
Market impact
This patent aims to enable the creation of a new class of pharmaceutical drugs based on psychedelic compounds, potentially expanding the market for mental health treatments. By developing novel psilocin analogs, it could lead to drug candidates with improved safety profiles or efficacy, allowing for broader clinical adoption. This could also spur further research and investment into the therapeutic potential of psychedelics, influencing drug development pipelines across the pharmaceutical industry.
Claim 1 — Plain English
What this patent covers
This patent focuses on creating new chemical compounds, referred to as "psilocin compounds" or "analogs," that are chemically similar to psilocin. These compounds are designed to act as "serotonin 5-HT2 receptor agonists," meaning they activate specific serotonin receptors in the brain. The goal is to use these new compounds in "pharmaceutical compositions" to treat medical conditions associated with these 5-HT2 receptors. For example, a new psilocin analog could be formulated into a pill to treat a mental health condition like depression, aiming to provide therapeutic benefits by modulating brain activity through these specific receptors. Due to the lack of available claims text, specific claim elements cannot be referenced.
The clever bit
The novelty lies in synthesizing new chemical structures, or 'analogs,' of psilocin. These analogs are engineered to interact with the brain's serotonin 5-HT2 receptors in specific ways, potentially offering advantages like improved stability, controlled duration of action, or reduced unwanted side effects compared to the natural compound.
What it does not cover
- Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives.
- Does not cover compounds that do not primarily function as 'serotonin 5-HT2 receptor agonists'.
- Does not cover non-chemical or non-pharmaceutical treatments for diseases associated with 5-HT2 receptors.
- Does not cover methods of use that are not for the treatment of diseases.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 15.4 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). New Psilocybin-Like Drugs for Brain Receptor Diseases (U.S. Patent No. 12,735,386). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12735386/psilocybin-analogs-salts-compositions-and-methods-of-use
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12735386"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does New Psilocybin-Like Drugs for Brain Receptor Diseases cover?
This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
Psilocybin and related compounds are being extensively researched for their potential to treat serious mental health conditions like depression, anxiety, and PTSD. This patent contributes to the development of novel drug candidates that could offer improved therapeutic profiles, such as better safety, efficacy, or duration of action, compared to naturally occurring psychedelics. It aims to expand the toolkit for addressing significant unmet medical needs in psychiatry and neurology.
What does this patent NOT cover?
Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives.
Patent monitoring